European Journal of Heart Failure最新文献

{"title":"Atrial fibrillation ablation in heart failure: which patients and which intervention?","authors":"Laurent Fauchier, Thibault Lenormand, Lisa Lochon","doi":"10.1093/ejhf/xuag276","DOIUrl":"https://doi.org/10.1093/ejhf/xuag276","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.3,"publicationDate":"2026-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148807994","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of altered ventricular function on atrial cardiomyopathy: a discordant phenomenon.","authors":"Andreas Goette","doi":"10.1093/ejhf/xuag254","DOIUrl":"https://doi.org/10.1093/ejhf/xuag254","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.3,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sex-specific familial aggregation of heart failure.","authors":"Andrea Barghetti, Johan Skov Bundgaard, Joel Mefford, Mischa Lundberg, Søren Albertsen Rand, Erik Sørensen, Ole Birger Pedersen, Christian Erikstrup, Andrew Schork, Henning Bundgaard, Sisse Rye Ostrowski","doi":"10.1093/ejhf/xuag272","DOIUrl":"https://doi.org/10.1093/ejhf/xuag272","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.3,"publicationDate":"2026-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond procedural success after TAVI: is multi-pillar heart failure therapy the next frontier?","authors":"Thorald Stolte, Thomas Nestelberger, Felix Mahfoud","doi":"10.1093/ejhf/xuag188","DOIUrl":"https://doi.org/10.1093/ejhf/xuag188","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.3,"publicationDate":"2026-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Persistent Atrial Myopathy Despite Ventricular Recovery: Prognostic Significance of Discordant LV-LA Strain Patterns in HFrEF.","authors":"Jiesuck Park, Nan Young Bae, Jaehyun Lim, Soongu Kwak, MinJung Bak, Hong-Mi Choi, Jun-Bean Park, Yeonyee E Yoon, Seung-Pyo Lee, Yong-Jin Kim, Goo-Yeong Cho, Hyung-Kwan Kim, In-Chang Hwang","doi":"10.1093/ejhf/xuag266","DOIUrl":"https://doi.org/10.1093/ejhf/xuag266","url":null,"abstract":"<p><strong>Aims: </strong>Assessment of treatment response in HFrEF has largely relied on left ventricular (LV)-centric parameters, yet the left atrium (LA) modulates LV filling and reflects the cumulative hemodynamic burden. Whether discordant recovery between LV and LA function carries distinct prognostic implications in patients treated with ARNI-based therapy remains unknown.</p><p><strong>Methods and results: </strong>From the multicentre STRATS-HF-ARNI registry, 1,182 patients with HFrEF who underwent serial echocardiography at baseline and one-year follow-up were included. Patients were classified according to the change in LVGLS and LASr at one year: Group A, concordant recovery (57.4%); Group B, discordant atrial non-recovery (11.2%); Group C, discordant ventricular non-recovery (15.6%); and Group D, concordant non-recovery (16.0%). Outcomes included all-cause mortality, cardiovascular mortality, and HF hospitalization. Despite achieving LV functional improvement, Group B exhibited persistent LASr deterioration, accompanied by less favourable hemodynamic trajectories than Group A. On multivariable Cox regression, Group B had significantly higher risks of all-cause mortality (adjusted hazard ratio [aHR] 3.53, 95% confidence interval [CI] 1.60-7.79) and cardiovascular mortality (aHR 5.68, 95% CI 1.91-16.92), comparable to Group D. Group C demonstrated higher HF hospitalization risk (aHR 2.25, 95% CI 1.31-3.86). The adverse prognostic impact of discordant atrial non-recovery was consistently observed across subgroups stratified by baseline LVGLS and LASr levels.</p><p><strong>Conclusion: </strong>In HFrEF patients treated with ARNI-based therapy, persistent LA dysfunction despite LV functional improvement identifies a high-risk phenotype comparable to concordant non-recovery. These findings suggest that concurrent assessment of LV and LA strain may provide incremental prognostic value beyond LV-centric metrics alone.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.3,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Strategies for preventing and reversing atrial cardiomyopathy (AtCM): current evidence, therapeutic targets, and future directions. A European Journal of Heart Failure expert consensus statement.","authors":"Rosita Zakeri, Massimiliano Camilli, Emilia D'Elia, Jean Sebastien Hulot, Massimo Iacoviello, Nicolò Sisti, Otilia Tica, Mariya Tokmakova, Jef Van den Eynde, Jerremy Weerts, Marco Metra, Wojciech Kosmala, Antoni Bayes-Genis","doi":"10.1093/ejhf/xuag268","DOIUrl":"https://doi.org/10.1093/ejhf/xuag268","url":null,"abstract":"<p><p>Atrial cardiomyopathy (AtCM) encompasses all forms of electrical atrial dysfunction in combination with mechanical atrial dysfunction, atrial enlargement and/or excessive atrial fibrosis. A growing body of evidence suggests that AtCM not only represents a consequence of ventricular and valvular heart disease but, critically, serves as the substrate driving atrial fibrillation (AF) and independently contributes to thromboembolic risk and heart failure (HF). Recent advances in cardiac imaging, electrocardiography, and electroanatomic mapping have enabled characterisation of AtCM and quantification of its severity, defining a continuum from atrial health to overt atrial failure. This framework creates an opportunity for targeted interventions that may reverse AtCM and prevent progression to clinical disease. This scientific statement summarises contemporary evidence regarding the natural history, determinants, and therapeutic modification of AtCM. We describe how targeted management of relevant lifestyle factors and comorbidities may prevent or attenuate AtCM progression and report the response of AtCM to pharmacological and structural interventions for HF and valve disease. Recognition of the bidirectional relationship between AtCM and AF has provided important insights into arrhythmia-mediated remodelling and generated the strongest evidence to date for reverse atrial remodelling following successful rhythm-control strategies. We also review emerging atrial-directed therapies targeting fibrosis, inflammation, metabolic dysfunction, and infiltrative disease. While AtCM appears to be, at least in part, a modifiable disease process, current evidence remains largely observational or mechanistic. We therefore highlight key evidence gaps and future research priorities to identify potentially reversible disease, develop targeted therapies, and translate state-of-the-art atrial phenotyping into improved patient outcomes.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.3,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786294","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Iron Deficiency and Bone Metabolism in Heart Failure.","authors":"Ryosuke Sato, Tania Garfias-Veitl, Angelika Hafke, Andreas Fischer, Guglielmo Fibbi, Mirela Vatic, Breno Wozne, Constanze Schmidt, Jürgen Kolos, Max Diesner, Thomas Bernd Dschietzig, Goran Loncar, John G F Cleland, Stefan D Anker, Stephan von Haehling","doi":"10.1093/ejhf/xuag259","DOIUrl":"https://doi.org/10.1093/ejhf/xuag259","url":null,"abstract":"<p><strong>Aims: </strong>Iron deficiency (ID) is common in chronic heart failure (HF) and may disturb bone metabolism.We investigated the association of ID with bone mineral density (BMD), and the potential mediating roles of fibroblast growth factor 23 (FGF-23) and 1,25-dihydroxy vitamin D (1,25(OH)2 vitamin D) in patients with chronic HF from the Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF).</p><p><strong>Methods and results: </strong>ID was defined as a transferrin saturation (TSAT) <20%. Among 198 patients (69 [61-76] years, 80% men), TSAT was <20% in 29.8% and associated with higher BMD (1.25 vs. 1.20 g/cm2, p=0.009), with a graded dose-response across TSAT quartiles (p for trend=0.0009). ID was also associated with higher serum FGF-23 (pg/mL; adjusted β=0.20, p=0.0009) and lower plasma 1,25(OH)2 vitamin D (30 vs. 35 pg/mL, p=0.03). In multivariable analyses, both TSAT <20% (adjusted odds ratio (aOR) 3.45, p=0.01) and lower plasma 1,25(OH)2 vitamin D (aOR 0.54, p=0.002) were associated with BMD above sex-specific medians.</p><p><strong>Conclusions: </strong>In HF, a TSAT <20% is associated with disturbed bone metabolism, possibly mediated by increases in serum FGF-23 and reductions in 1,25(OH)2 vitamin D concentrations. Detailed analyses of bone microstructure in HF are warranted.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.3,"publicationDate":"2026-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148786237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to letter \"Urinary Sodium Thresholds Require a Defined Diuretic Challenge\".","authors":"Jan Biegus, Gracjan Iwanek, Piotr Ponikowski","doi":"10.1093/ejhf/xuag261","DOIUrl":"10.1093/ejhf/xuag261","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.3,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148756867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Finerenone and apparent treatment-resistant hypertension in heart failure with mildly reduced or preserved ejection fraction.","authors":"John W Ostrominski, Brian L Claggett, Ian J Kulac, Akshay S Desai, Pardeep S Jhund, Alasdair Henderson, Carolyn S P Lam, Michele Senni, Sanjiv J Shah, Adriaan A Voors, Faiez Zannad, Bertram Pitt, Meike Brinker, Patrick Schloemer, Flaviana Amarante, Lucas Hofmeister, John J V McMurray, Scott D Solomon, Muthiah Vaduganathan","doi":"10.1093/ejhf/xuag209","DOIUrl":"https://doi.org/10.1093/ejhf/xuag209","url":null,"abstract":"<p><strong>Aims: </strong>Apparent treatment-resistant hypertension (aTRH) is common and associated with adverse outcomes in individuals with heart failure (HF) with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Whether finerenone improves blood pressure (BP) and clinical outcomes in individuals with HFmrEF/HFpEF and aTRH is uncertain.</p><p><strong>Methods: </strong>In this pre-specified analysis of the FINEARTS-HF trial, participants were categorized according to baseline BP, with aTRH defined as BP ≥140/90 mm Hg (≥130/80 mm Hg if diabetes) despite treatment with ≥3 BP-lowering medications, including a diuretic. Non-resistant hypertension was defined as BP above threshold but not meeting aTRH criteria. Controlled BP was defined as BP under the threshold. Incidence of clinical outcomes and safety events was assessed by baseline hypertension category.</p><p><strong>Results: </strong>Among 6001 participants, 3471 (57.8%) had controlled blood pressure, 1754 (29.2%) had non-resistant hypertension, and 776 (12.9%) had aTRH at baseline. Between baseline and 36 months, finerenone similarly reduced systolic BP across baseline BP categories (Pinteraction = 0.59). Rates of cardiovascular death and total HF events (per 100 person-years) were 17.0 in those with controlled BP, 16.0 in those with non-resistant hypertension, and 13.8 in those with aTRH (Pcomparison = 0.12). Relative treatment benefits of finerenone vs placebo on the primary outcome (Pinteraction = 0.32) and HF-related health status (Pinteraction = 0.22) were consistent across hypertension categories. The safety profile of finerenone vs placebo did not appear to be modified by baseline hypertension category.</p><p><strong>Conclusion: </strong>aTRH was identified in 1-in-8 individuals with HFmrEF/HFpEF in FINEARTS-HF. Finerenone consistently improved clinical outcomes, health status, and blood pressure, including among those with aTRH.</p>","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.3,"publicationDate":"2026-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148758455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Target-dose ACE inhibitors in HFrEF: does agent-specific pharmacokinetics matter in advanced CKD?","authors":"Kashaf Ikhlas, Ahmad Khubaib Zafar","doi":"10.1093/ejhf/xuag252","DOIUrl":"https://doi.org/10.1093/ejhf/xuag252","url":null,"abstract":"","PeriodicalId":164,"journal":{"name":"European Journal of Heart Failure","volume":" ","pages":""},"PeriodicalIF":10.3,"publicationDate":"2026-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148758546","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}